Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Mitotaneis a highly potent antineoplastic drug specifically designed to treat inoperable adrenocortical carcinoma and Cushing syndrome.What are the side effects of using Mitotane?T···【more】
Article source：Captain MedicineRelease date：2024-08-19Recommended：355
Anamoreline is the world's first drug for the treatment of cancer cachexia, which was launched in Japan in 2021; By activating ghrelin receptors, it increases appetite and prom···【more】
Article source：Captain MedicineRelease date：2024-08-19Recommended：284
Anamorelin, a drug that specializes in the treatment of cancer cachexia, was launched in Japan in 2021. Anamorelin helps patients increase their appetite and weight by mimicking th···【more】
Article source：Captain MedicineRelease date：2024-08-19Recommended：252
Mitotane, commonly used in the form of tablets, is a highly effective antineoplastic drug for adrenal adenoma without surgical conditions. It is also effective for Cushing syndrome···【more】
Article source：Captain MedicineRelease date：2024-08-19Recommended：302
Mitotane tablets are commonly used in dosage form and are highly effective antineoplastic drugs. We specialize in inoperable adrenocortical tumors and broaden the treatment pathway···【more】
Article source：Captain MedicineRelease date：2024-08-19Recommended：292
Mitotane, which is often made in tablet form, is a highly effective antineoplastic drug. It is mainly used to treat adrenal cortical tumors that cannot be operated on, providing pa···【more】
Article source：Captain MedicineRelease date：2024-08-19Recommended：342
Selpercatinib is a targeted therapy drug specifically designed to fight various cancers associated with the RET gene; By inhibiting specific kinases, they interfere with the growth···【more】
Article source：Captain MedicineRelease date：2024-08-19Recommended：367
Selpercatinib is a drug that targets mutations in the RET gene and is suitable for a variety of cancers caused by RET fusions or mutations. It stops the growth and spread of tumors···【more】
Article source：Captain MedicineRelease date：2024-08-19Recommended：261
In 2020, Selpercatinib was approved by the FDA as the first highly selective RET inhibitor for the treatment of a variety of cancers caused by RET gene fusions and mutations. It ef···【more】
Article source：Captain MedicineRelease date：2024-08-19Recommended：335
In May 2020, Selpercatinib received FDA approval as a breakthrough drug for the treatment of RET gene fusion and mutant cancers. It is especially suitable for adult and pediatric p···【more】
Article source：Captain MedicineRelease date：2024-08-19Recommended：347
As a novel anti-cancer drug, Selpercatinib can treat solid tumors associated with RET gene mutations. By interfering with key signaling pathways of cancer cells, it effectively slo···【more】
Article source：Captain MedicineRelease date：2024-08-19Recommended：367
Selpercatinib is a targeted drug designed for the treatment of non-small cell lung cancer, targeting RET gene mutations, and the mechanism of action is to limit the spread of cance···【more】
Article source：Captain MedicineRelease date：2024-08-19Recommended：379
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4432025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6302024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：852026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：4132025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4282025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4152025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4732025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3832025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
